405 related articles for article (PubMed ID: 26174047)
21. Berberine derivatives reduce atherosclerotic plaque size and vulnerability in apoE(-/-) mice.
Chen J; Cao J; Fang L; Liu B; Zhou Q; Sun Y; Wang Y; Li Y; Meng S
J Transl Med; 2014 Nov; 12():326. PubMed ID: 25425200
[TBL] [Abstract][Full Text] [Related]
22. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota.
Wang Y; Tong Q; Ma SR; Zhao ZX; Pan LB; Cong L; Han P; Peng R; Yu H; Lin Y; Gao TL; Shou JW; Li XY; Zhang XF; Zhang ZW; Fu J; Wen BY; Yu JB; Cao X; Jiang JD
Signal Transduct Target Ther; 2021 Feb; 6(1):77. PubMed ID: 33623004
[TBL] [Abstract][Full Text] [Related]
23. Berberine alleviates intestinal barrier dysfunction in glucolipid metabolism disorder hamsters by modulating gut microbiota and gut-microbiota-related tryptophan metabolites.
Chen Y; Hao Z; Zhao H; Duan X; Jia D; Li K; Yang Y; Cui H; Gao M; Zhao D
J Sci Food Agric; 2023 Feb; 103(3):1464-1473. PubMed ID: 36168925
[TBL] [Abstract][Full Text] [Related]
24. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge.
Xu HY; Liu CS; Huang CL; Chen L; Zheng YR; Huang SH; Long XY
Colloids Surf B Biointerfaces; 2019 Sep; 181():927-934. PubMed ID: 31382342
[TBL] [Abstract][Full Text] [Related]
25. Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR's cholesterol-decreasing efficacy in patients.
Wu C; Zhao Y; Zhang Y; Yang Y; Su W; Yang Y; Sun L; Zhang F; Yu J; Wang Y; Guo P; Zhu B; Wu S
J Adv Res; 2022 Mar; 37():197-208. PubMed ID: 35499044
[TBL] [Abstract][Full Text] [Related]
26. Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation.
Tian Y; Cai J; Gui W; Nichols RG; Koo I; Zhang J; Anitha M; Patterson AD
Drug Metab Dispos; 2019 Feb; 47(2):86-93. PubMed ID: 30409838
[TBL] [Abstract][Full Text] [Related]
27. Berberine alleviates lipid metabolism disorders via inhibition of mitochondrial complex I in gut and liver.
Yu M; Alimujiang M; Hu L; Liu F; Bao Y; Yin J
Int J Biol Sci; 2021; 17(7):1693-1707. PubMed ID: 33994854
[TBL] [Abstract][Full Text] [Related]
28. Responses of human gut microbiota abundance and amino acid metabolism
Fu Y; Wang Y; Wang X; Sun Y; Ren J; Fang B
Food Funct; 2022 Jun; 13(11):6329-6337. PubMed ID: 35611943
[TBL] [Abstract][Full Text] [Related]
29. Berberine treatment-emergent mild diarrhea associated with gut microbiota dysbiosis.
Yue SJ; Liu J; Wang WX; Wang AT; Yang XY; Guan HS; Wang CY; Yan D
Biomed Pharmacother; 2019 Aug; 116():109002. PubMed ID: 31154270
[TBL] [Abstract][Full Text] [Related]
30. Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota.
Zhang ZW; Cong L; Peng R; Han P; Ma SR; Pan LB; Fu J; Yu H; Wang Y; Jiang JD
J Pharm Anal; 2021 Oct; 11(5):628-637. PubMed ID: 34765276
[TBL] [Abstract][Full Text] [Related]
31. The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression.
Yang YN; Wang QC; Xu W; Yu J; Zhang H; Wu C
Biomed Pharmacother; 2022 Nov; 155():113749. PubMed ID: 36174380
[TBL] [Abstract][Full Text] [Related]
32. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function.
Shan YQ; Zhu YP; Pang J; Wang YX; Song DQ; Kong WJ; Jiang JD
Biol Pharm Bull; 2013; 36(10):1562-9. PubMed ID: 23924821
[TBL] [Abstract][Full Text] [Related]
33. Toxicological assessment of dihydroberberine.
Lewis KD; Falk M
Food Chem Toxicol; 2022 Oct; 168():113301. PubMed ID: 35868606
[TBL] [Abstract][Full Text] [Related]
34. Enhancing effects of chitosan and chitosan hydrochloride on intestinal absorption of berberine in rats.
Chen W; Fan D; Meng L; Miao Y; Yang S; Weng Y; He H; Tang X
Drug Dev Ind Pharm; 2012 Jan; 38(1):104-10. PubMed ID: 21774632
[TBL] [Abstract][Full Text] [Related]
35. The mechanism of berberine alleviating metabolic disorder based on gut microbiome.
Wang H; Zhang H; Gao Z; Zhang Q; Gu C
Front Cell Infect Microbiol; 2022; 12():854885. PubMed ID: 36093200
[TBL] [Abstract][Full Text] [Related]
36. Berberine combined with stachyose induces better glycometabolism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice.
Li CN; Wang X; Lei L; Liu MZ; Li RC; Sun SJ; Liu SN; Huan Y; Zhou T; Liu Q; Cao H; Bai GL; Han YW; Shen ZF
Phytother Res; 2020 May; 34(5):1166-1174. PubMed ID: 31833107
[TBL] [Abstract][Full Text] [Related]
37. Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota.
Ma SR; Tong Q; Lin Y; Pan LB; Fu J; Peng R; Zhang XF; Zhao ZX; Li Y; Yu JB; Cong L; Han P; Zhang ZW; Yu H; Wang Y; Jiang JD
Signal Transduct Target Ther; 2022 Jul; 7(1):207. PubMed ID: 35794102
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Berberine Bioavailability between Oral and Rectal Administrations in Rats.
Mori N; Oda K; Takakura H; Tanaka Y; Yokooji T; Murakami T
Biol Pharm Bull; 2023; 46(11):1639-1642. PubMed ID: 37914368
[TBL] [Abstract][Full Text] [Related]
39. In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine.
Yang N; Sun RB; Chen XL; Zhen L; Ge C; Zhao YQ; He J; Geng JL; Guo JH; Yu XY; Fei F; Feng SQ; Zhu XX; Wang HB; Fu FH; Aa JY; Wang GJ
Acta Pharmacol Sin; 2017 Mar; 38(3):351-361. PubMed ID: 28042874
[TBL] [Abstract][Full Text] [Related]
40. Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties.
Murakami T; Bodor E; Bodor N
Expert Opin Drug Metab Toxicol; 2023 Mar; 19(3):129-137. PubMed ID: 37057922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
